Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Summary
Third Opinion Trial Synopsis:
This is a study to see if using two different sets of drugs can help more patients with a certain disease become healthier. They will use a combination of drugs called "DaraRd" and "DRVd" to see if they are better than the usual treatment. They will only use the second set of drugs for patients who still have the disease after the first treatment. The doctors will decide how long to give the drugs based on each patient's situation.
This is a study to see if using two different sets of drugs can help more patients with a certain disease become healthier. They will use a combination of drugs called "DaraRd" and "DRVd" to see if they are better than the usual treatment. They will only use the second set of drugs for patients who still have the disease after the first treatment. The doctors will decide how long to give the drugs based on each patient's situation.
*Third Opinion AI Generated Synopsis
Trial Summary
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy. This is a study based on adaptive design for decision making of treatment options. Duration of therapy (daratumumab cycles) will depend on individual approach, response, evidence of disease progression and tolerance.
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy. This is a study based on adaptive design for decision making of treatment options. Duration of therapy (daratumumab cycles) will depend on individual approach, response, evidence of disease progression and tolerance.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
